Trial Profile
A retrospective study evaluating efficacy of direct acting antiviral agents in hepatitis C patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir/sofosbuvir (Primary) ; Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 09 Mar 2017 New trial record
- 01 Feb 2017 Results published in the International Journal of Clinical PharmacyConference: 45th ESCP-NSF International Symposium on Clinical Pharmacy: Clinical Pharmacy Tackling Inequalities and Access to Health Care Norway